دورية أكاديمية
أعرض في EDS

Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study.

التفاصيل البيبلوغرافية
العنوان: Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study.
المؤلفون: Ng T; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore.; Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore., Lee YY; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore., Chae JW; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore.; Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore., Yeo AHL; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore., Shwe M; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore., Gan YX; Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore., Ng RCH; Duke-NUS Medical School Singapore, Singapore, Singapore.; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Chu PPY; Singapore Cord Blood Bank, K.K. Women's and Children's Hospital, Singapore, Singapore., Khor CC; Genome Institute of Singapore, Singapore, Singapore., Ho HK; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore., Chan A; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore. phaac@nus.edu.sg.; Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore. phaac@nus.edu.sg.; Duke-NUS Medical School Singapore, Singapore, Singapore. phaac@nus.edu.sg.
المصدر: BMC cancer [BMC Cancer] 2017 Dec 19; Vol. 17 (1), pp. 867. Date of Electronic Publication: 2017 Dec 19.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Genetic Predisposition to Disease*, Brain-Derived Neurotrophic Factor/*genetics , Breast Neoplasms/*drug therapy , Breast Neoplasms/*genetics, Adult ; Aged ; Brain-Derived Neurotrophic Factor/blood ; Breast Neoplasms/blood ; Breast Neoplasms/pathology ; Cognitive Dysfunction/chemically induced ; Cognitive Dysfunction/pathology ; Female ; Genetic Association Studies ; Genotype ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Polymorphism, Single Nucleotide
مستخلص: Background: Preliminary evidence suggests that changes in plasma brain-derived neurotrophic factor (BDNF) levels may contribute to the occurrence of chemotherapy-associated cognitive impairment (CACI), and a previous study suggested that carriers of the BDNF Met homozygous genotype are protected from CACI.
Methods: This multicenter, prospective cohort study involved chemotherapy-receiving early-stage breast cancer (ESBC) patients. Self-perceived cognitive function was longitudinally assessed using the validated FACT-Cog (ver. 3) across three time points: Prior to chemotherapy (T1), during chemotherapy (T2), and at the end of chemotherapy (T3). Plasma BDNF levels were quantified using enzyme-linked immunosorbent assay. Genotyping was performed using Sanger Sequencing.
Results: A total of 51 chemotherapy-receiving ESBC patients (mean age: 52.6 ± 9.5 years) were recruited, and 11 patients (21.6%) reported subjective cognitive impairment post-chemotherapy. Overall, there was a reduction in median plasma BDNF levels over time (T1: 5423.0 pg/ml; T2: 5313.6 pg/ml; T3: 4050.3 pg/ml; p < 0.01). After adjusting for confounding factors, longitudinal analysis revealed that BDNF levels were associated with self-reported concentration deficit (p = 0.032). Carriers of Val/Val (p = 0.011) and Val/Met (p = 0.003) BDNF genotypes demonstrated a significant reduction in plasma BDNF levels over time; however, plasma BDNF levels were similar across all time points among Met homozygous carriers (p = 0.107).
Conclusion: There was a statistically significant change in BDNF levels post-chemotherapy in ESBC patients, and plasma BDNF levels were associated with self-perceived concentration deficit in patients receiving chemotherapy.
References: J Neuropathol Exp Neurol. 2012 Apr;71(4):289-97. (PMID: 22437340)
Front Aging Neurosci. 2014 Apr 15;6:69. (PMID: 24782766)
Ann Oncol. 2012 Oct;23(10):2547-52. (PMID: 22396443)
Hum Genet. 2012 Jul;131(7):1187-95. (PMID: 22362486)
J Cell Biol. 2009 May 18;185(4):727-41. (PMID: 19451278)
Neuropharmacology. 1998 Dec;37(12):1553-61. (PMID: 9886678)
Growth Factors. 2004 Sep;22(3):123-31. (PMID: 15518235)
PLoS One. 2009;4(5):e5424. (PMID: 19412541)
Ann Oncol. 2015 Jul;26(7):1446-51. (PMID: 25922060)
Biol Psychiatry. 2007 Apr 1;61(7):911-22. (PMID: 17217930)
Psychol Med. 2015 Mar;45(4):841-54. (PMID: 25162472)
Int J Neuropsychopharmacol. 2011 Apr;14(3):347-53. (PMID: 20604989)
Support Care Cancer. 2017 Feb;25(2):633-643. (PMID: 27771785)
J Geriatr Psychiatry Neurol. 2008 Sep;21(3):166-70. (PMID: 18503034)
J Psychiatr Res. 2007 Aug;41(5):387-94. (PMID: 16554070)
Cancer. 1999 Mar 1;85(5):1186-96. (PMID: 10091805)
J Neurosci. 2005 Jun 1;25(22):5455-63. (PMID: 15930396)
Science. 2001 Nov 30;294(5548):1945-8. (PMID: 11729324)
PLoS One. 2014 Mar 26;9(3):e91339. (PMID: 24670553)
Nature. 1986 Feb 27-Mar 5;319(6056):774-6. (PMID: 2869411)
Lancet Oncol. 2011 Jul;12(7):703-8. (PMID: 21354373)
Neuro Oncol. 2016 Feb;18(2):244-51. (PMID: 26289590)
Biomark Med. 2010 Dec;4(6):871-87. (PMID: 21133708)
Science. 2004 Oct 15;306(5695):487-91. (PMID: 15486301)
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1267-72. (PMID: 19147841)
Neuron. 2003 Aug 28;39(5):735-8. (PMID: 12948441)
Value Health. 2013 Sep-Oct;16(6):1001-13. (PMID: 24041350)
J Clin Epidemiol. 2014 Jul;67(7):811-20. (PMID: 24656406)
World J Biol Chem. 2014 Nov 26;5(4):409-28. (PMID: 25426265)
J Clin Psychiatry. 2008 Jul;69(7):1104-11. (PMID: 18505307)
PLoS One. 2012;7(4):e35217. (PMID: 22523577)
معلومات مُعتمدة: NMRC/CIRG/1386/2014 National Medical Research Council
فهرسة مساهمة: Keywords: BDNF; Breast cancer; Cognition; Genetics; rs6265
المشرفين على المادة: 0 (Brain-Derived Neurotrophic Factor)
7171WSG8A2 (BDNF protein, human)
تواريخ الأحداث: Date Created: 20171221 Date Completed: 20180723 Latest Revision: 20181113
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5735945
DOI: 10.1186/s12885-017-3861-9
PMID: 29258453
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2407
DOI:10.1186/s12885-017-3861-9